Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2006 December;61(6) > Minerva Chirurgica 2006 December;61(6):467-71

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CHIRURGICA

A Journal on Surgery


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,115


eTOC

 

ORIGINAL ARTICLES  


Minerva Chirurgica 2006 December;61(6):467-71

Copyright © 2006 EDIZIONI MINERVA MEDICA

language: English

Lung cancer after treatment for non-Hodgkin lymphoma

De Giacomo T., Martelli M., Venuta F., Anile M., Diso D., Di Stasio M., Rendina E. A., Coloni G. F.

1 Department of Thoracic Surgery University of Rome “La Sapienza”, Rome, Italy 2 Department of Haematology University of Rome “La Sapienza”, Rome, Italy


PDF  


Aim. Because of the improvement in treatment and survival of patients with lymphoma, late sequelae, including secondary cancers have been extensively studied. Lung cancer is one of the two most common solid tumors after Hodgkin’s disease but fewer studies have been published about lung cancer after non-Hodgkin lymphoma (NHL).
Methods. Over the last five years at our Institution we have observed 16 patients, 13 male and 3 female, with a mean age of 61 years, previously treated for NHL and lung cancer. Median latency between NHL and lung cancer was 7 years. In 6 patients (37.5%) the latency period was shorter than 5 years and 3 of them developed lung cancer within 2 years after the end of NHL therapy.
Results. Ten patients underwent lung complete resection. Two, 3 and 5 year survival rate was respectively 52.7%, 26.3% and 13%. In contrast, the median survival of non surgical patients was 9 months. Comparison of survival between surgical and non-surgical group demonstrated a statistically significant better survival for surgically treated patients (P<0.04).
Conclusions. Surgery can improve survival in patients with history of NHL and lung cancer. Early diagnosis and treatment is crucial. NHL survivors should undergo careful follow-up and surveillance for secondary malignancy.

top of page

Publication History

Cite this article as

Corresponding author e-mail